Serum α-fetoprotein level per tumor volume reflects prognosis in patients with hepatocellular carcinoma after curative hepatectomy

Hepato-Gastroenterology

Volumn 55, Issue 86-87, 2008, Pages 1705-1709

  Furihata, Tadashi ^a   Sawada, Tokihiko ^a   Kita, Junji ^a   Iso, Yukihiro ^a   Kato, Masato ^a   Rokkaku, Kyu ^a   Shimoda, Mitsugi ^a   Kubota, Keiichi ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

fetoprotein; Disease free survival period; Hepatocellular carcinoma; Prognosis; Survival curve

Indexed keywords

ALPHA FETOPROTEIN; INDOCYANINE GREEN;

AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CORRELATION ANALYSIS; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME; TUMOR VOLUME;

ADULT; AGED; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS;

EID: 57049179579     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Okuda K, Ohtsuki T, Obata M, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, Ohnishi K: Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer 1985; 56:918-928.
2. Talerman A, Haije WG, Baggerman L: Serum a fetoprotein in patients with germ cell tumors of the gonads and extragonadal sites: Correlation between endodermal sinus (yolk sac) tumor and raised serum αFP. Cancer 1980; 46:380-385.
3. Daniele B, Bencivenga A, Megna AS, Tinessa V: a fetoprotein and ultrasonography for hepatocellular carcinoma. Gastroenterology 2004; 52:108-112.
4. Di Bisceglie AM: Issues in screening and surveillance for hepatocellular carcinoma. Gastroenterology 2004; 127:104-107.
5. Gutpa S, Bent S, Kohlwes J: Test characteristics of a fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. Ann Inter Med 2003; 139:46-49.
6. Trevisani F, D'Intino PE, Morselli-Labete AM, Mazzella G, Accoqli E, Caraceni P, Domenicali M, De Notariis S, Roda E, Bernardi M: Serum α fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HbsAg and anti-HCV status. J Hepatol 2001; 34:570-575.
7. Colombo M: Screening for cancer in viral hepatitis. Clin Liver Dis 2001; 5:109-122.
8. Cottone M, Turri M, Caltagirone M, Parisi P, Orlando A, Fiorentino G, Virdone R, Fusco G, Grasso R, Simonetti RG: Screening for hepatocellular carcinoma in patients with Childs A cirrhosis: An 8 year prospective study by ultrasound and α fetoprotein. J Hepatol 1994; 21:1029-1034.
9. Collier J, Sherman M: Screening for hepatocellular carcinoma. Hepatology 1998; 27:273-278.
10. Chen DS, Sung JL: Serum alpha-fetoprotein in hepatocellular carcinoma. Cancer 1977; 27:779-783.
11. Shen JC, Huang GT, Chen DS, Lai MY, Wang TH, Yu JY, Yang PM, Chuang CN, Yang PC, Lee CS, Hsu HC, How SW: Early detection of hepatocellular carcinoma by real time ultrasonography: a prospective study. Cancer 1985; 56:660-666.
12. Lai CL, Gregory PB, Wu PC, Lok AS, Wong KP, Nq MM: Hepatocellular carcinoma in Chinese males and females: possible causes for male predominance. Cancer 1987; 60:1107-1110.
13. Fabio F, Dario M, Massimo DG: Diagnositic and prognostic role of α-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol 2006; 101:524-532.
14. Tangkijvanich P, Anukulkarnkusol N, Suwangool P, Lertmaharit S, Hanvivatvong O, Kullavanijaya P, Poovorawan Y: Clinical characteristics and prognosis of hepatocellular carcinoma. Analysis based in serum α fetoprotein levels. J Clin Gastroenterol 2000; 31:302-308.
15. Guidelines for the Clinical and Pathological Studies on Hepatocellular Carcinoma. Japanese Society of Hepatocellular Carcinoma, 1999.
16. Kubota K, Makuuchi M, Kusaka K, Kobayashi T, Miki K, Hasegawa K, Harihara Y, Takayama T: Measurement of liver volume and hepatic functional reserve as a guide to decision-marking in resectional surgery for hepatic tumors. Hepatology 1997; 26:1176-1181.
17. Nomura F, Ohnishi K, Tanabe Y: Clinical features and prognosis of hepatocellular carcinoma with reference to serum a fetoprotein levels. Analysis of 606 patients. Cancer 1989; 64:1700-1707.
18. Peng SY, Chen WJ, Lai PL, Jeng YM, Sheu JC, Hsu HC: High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: Significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int J Cancer 2004; 112:44-50.
19. Alpart E, Starzl TE, Schur PH: Serum-fetoprotein in hepatoma patients after liver transplantation. Gastroenterology 1971; 61:144-148.
20. Nomura F, Ohnishi K, Honda M, Satomura Y, Nakai T, Okuda K: Clinical features of hepatocellular carcinoma in the elderly: a study of 91 patients older than 70 years. Br J Cancer 1994; 70:690-693.
21. Chlebowski RT, Tong M, Weissman J, Block JB, Ramming KP, Weiner JM, Bateman JR, Chlebowski JS: Hepatocellular carcinoma. Diagnostic and prognostic features in North American patients. Cancer 1984; 53:2701-2706.
22. Attali P, Prod'Homme S, Pelletier G, Papoz L, Ink O, Buffet C, Etienne JP: Prognostic factor in patients with hepatocellular carcinoma. Attempts for the selection of patients with prolonged survival. Cancer 1987; 59:2108-2111.
23. Yamashita Y, Takahashi M, Koga Y, Saito R, Nanakawa S, Hatanaka Y, Sato N, Nakashima K, Urata J, Yoshizumi K, Ito K, Sumi S, Kan M: Prognostic factors in the treatment of hepatocellular carcinoma with transcatheter arterial embolization and arterial infusion. Cancer 1991; 67:385-391.
24. Muguti G, Tait N, Richardson A, Little JM: Alpha-fetoprotein expression in hepatocellular carcinoma: a clinical study. J Gastroenterol Hepatol 1992; 7:374-378.
25. Stuart KE, Anand AJ, Jenkins RL: Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer 1996; 77:2217-2222.
26. Goroq D, Regoly-Merei J, Paku S, Kopper L, Naqy P: α-fetoprotein expression is a potential prognostic marker in hepatocellular carcinoma. World J Gastroenterol 2005; 11:5015-5018.